Egle A - Search Results

1

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Pleyer L, Egle A, Hartmann TN, Greil R. Pleyer L, et al. Among authors: egle a. Nat Rev Clin Oncol. 2009 Jul;6(7):405-18. doi: 10.1038/nrclinonc.2009.72. Epub 2009 Jun 2. Nat Rev Clin Oncol. 2009. PMID: 19488076 Review.

2

Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.

Villunger A, Egle A, Kos M, Hittmair A, Maly K, Greil R. Villunger A, et al. Among authors: egle a. Int J Cancer. 1996 Feb 8;65(4):498-505. doi: 10.1002/(SICI)1097-0215(19960208)65:4<498::AID-IJC18>3.0.CO;2-6. Int J Cancer. 1996. PMID: 8621234

3

2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).

Gruber J, Geisen F, Sgonc R, Egle A, Villunger A, Boeck G, Konwalinka G, Greil R. Gruber J, et al. Among authors: egle a. Stem Cells. 1996 May;14(3):351-62. doi: 10.1002/stem.140351. Stem Cells. 1996. PMID: 8724701

4

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

Egle A, Marschitz I, Posch B, Herold M, Greil R. Egle A, et al. Br J Haematol. 1996 Jul;94(1):211-2. Br J Haematol. 1996. PMID: 8757538 No abstract available.

5

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

Egle A, Villunger A, Kos M, Böck G, Gruber J, Auer B, Greil R. Egle A, et al. Eur J Immunol. 1996 Dec;26(12):3119-26. doi: 10.1002/eji.1830261244. Eur J Immunol. 1996. PMID: 8977313

6

The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.

Geley S, Hartmann BL, Kapelari K, Egle A, Villunger A, Heidacher D, Greil R, Auer B, Kofler R. Geley S, et al. Among authors: egle a. FEBS Lett. 1997 Jan 27;402(1):36-40. doi: 10.1016/s0014-5793(96)01496-2. FEBS Lett. 1997. PMID: 9013854 Free article.

7

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.

Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R. Egle A, et al. Br J Haematol. 1997 May;97(2):418-28. doi: 10.1046/j.1365-2141.1997.382680.x. Br J Haematol. 1997. PMID: 9163609 Free article.

8

Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.

Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, Geley S, Kofler R, Greil R. Villunger A, et al. Among authors: egle a. Blood. 1997 Jul 1;90(1):12-20. Blood. 1997. PMID: 9207432 Free article.

9

Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.

Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Villunger A, et al. Among authors: egle a. Cancer Res. 1997 Aug 15;57(16):3331-4. Cancer Res. 1997. PMID: 9269989

10

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R. Tinhofer I, et al. Among authors: egle a. Blood. 1998 Jun 1;91(11):4273-81. Blood. 1998. PMID: 9596676 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters